Interstitial pneumonitis related to rituximab therapy for Waldenström's macroglobulinemia

Rituximab‐combined therapeutic regimens have been recommended for treatment of Waldenström's Macroglobulinemia (WM). We report one WM patient who developed interstitial pneumonitis after rituximab therapy.

[1]  C. Kyriakou,et al.  Guidelines on the diagnosis and management of Waldenström macroglobulinaemia , 2014, British journal of haematology.

[2]  M. Kersten,et al.  Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  E. Chilvers,et al.  Non-infectious pulmonary toxicity of rituximab: a systematic review. , 2012, Rheumatology.

[4]  U. Metser,et al.  Fatal interstitial pneumonitis related to rituximab-containing regimen. , 2006, Clinical lymphoma & myeloma.

[5]  R. Kaczmarski,et al.  Interstitial pneumonitis related to rituximab therapy. , 2003, The New England journal of medicine.